Ask about this productRelated genes to: CD3e antibody
- Gene:
- CD3E NIH gene
- Name:
- CD3e molecule
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 11q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: CD3e antibody
Related articles to: CD3e antibody
- NRF2 modulates tumor immune microenvironment in several cancers. NRF2 is activated in about 50% of high-grade serous ovarian cancer (HGSOC), the most aggressive type of ovarian cancer. Through analyzing data from scRNA-seq (n = 7), bulk RNA-seq (n = 365), and tumor microarray (TMA) of human HGSOC (n = 240) samples, we demonstrated that NRF2 expression correlated with tumor immune microenvironment in HGSOC. Functional pathway enrichment analysis and transcription factors (TFs) prediction showed the functional relevance of NRF2 expression in shaping the immune phenotype of HGSOC. Pathways such as hedgehog and ROS signaling, and TFs including EGR1, ESRRA, SMAD proteins, and SP-family proteins, are implicated in the immune suppressive microenvironment of NRF2 tumors. Immune differentiation analysis showed patients with NRF2 tumors enriched with CD68 have lower survival (p = 0.038) than those with CD68 tumors, whereas NRF2 tumors enriched with immune-activated markers such as CD3E and CD80 exhibit a better prognosis. This study is the first that shows classification of HGSOC based on NRF2 levels, highlights new biomarkers, and suggests IHC-labeling and genomic evaluation of NRF2 and immune markers for better prognosis. - Source: PubMed
Publication date: 2026/04/28
Hamad Samera HKatz ChelseaToma HelenMurakami KosukeBendjilali NasrineZhu GordShojaei HadiFang LanlanLeung SamuelKoebel MartinKaraduman HuseyinAbinader OliverMitra RamkrishnaKrill LaurenChu ChristinaWarshal David PWang Yemin - The development of anti-CD3 antibody-based T cell engager therapeutics has improved the treatment of various malignancies, yet the challenge of achieving tumor-specific targeting while minimizing on-target off-tumor effects in normal tissues remains a substantial hurdle. One promising strategy to address this issue involves engineering antibodies with conditional pH-dependent binding affinities, capitalizing on the acidic microenvironment characteristics of tumors (pH ~ 6.5-6.8) compared to the neutral pH of healthy tissues (pH ~ 7.4). In this study, we focus on the pH-engineering of antibody binders against the human CD3 antigen, a critical component of T cell activation, to achieve preferential binding at acidic pH. Using molecular dynamics (MD) simulations on the reported CD3ɛ antibody binder 40G5c, we shed light on possible molecular mechanisms of the pH-responsiveness of key mutations and their impact on the overall binder structure at physiological or acidic pH. Our study highlights how MD has emerged as a powerful tool to guide and explain intrinsic pH-dependent molecular mechanisms in antibody engineering. Lastly, we report that our engineered CD3 binders preferentially bind and activate T cells under acidic pH conditions and display favorable affinity and pH-window profiles. - Source: PubMed
Publication date: 2026/04/27
La Sala GrégoryKroell Katharina BPincha MuditaGassner ChristianDeho LorenzoMoessner EkkehardGueripel XavierBorin NicoleClassen MoritzBenz JörgBujotzek AlexanderKlein ChristianGeorges GuyHugenmatter AdrianLiedl Klaus RVangone Anna - This study aimed to identify key molecular signatures and therapeutic targets in early sepsis through integrated bioinformatics analysis. - Source: PubMed
Publication date: 2026/03/23
Gai XiaoweiLi YaqingWang YananGao DanWu ShanshanGeng YananZhang JiaminYao MinghuiYao GaiqiWang Qiuyan - T-cell lymphomas (TCLs) account for a relatively small fraction of lymphoid malignancies and are characterized by highly aggressive course often refractory to current available therapies. We previously reported potent in vitro and in vivo antitumor activity of a Bispecific T-Cell Engager (UMG1/CD3ε-BTCE) directed against UMG1, a unique CD43 epitope that is abundantly expressed on T-cell acute lymphoblastic leukemia (T-ALL) and diffuse large B-cell lymphoma (DLBCL) cells, while absent in most normal tissues, except thymocytes and a small fraction of peripheral blood T lymphocytes (< 5%). Here, we investigated the in vitro efficacy of UMG1/CD3ε-BTCE against TCLs. IHC analysis of Tissue Micro Arrays (TMAs) revealed high UMG1 expression in 62.3% of TCL samples, including peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and ALK-negative anaplastic large cell lymphoma (ALCL). Notably, all T-PLL primary specimens (27/27) were positive, and 3 of 4 TCL cell lines also expressed UMG1 by flow cytometry. The asymmetric UMG1/CD3ε-BTCE induced robust redirected cytotoxicity against UMG1-expressing TCL cells. Moreover, this activity was strengthened by cell exposure to the HDAC inhibitor SAHA. We observed a dose-dependent engaged T-cell-mediated cytotoxicity and inflammatory cytokine release, resulting in lysis of UMG1-expressing cells, with no significant effect on UMG1-not expressing cells. Our findings suggest that the UMG1/CD3ε-BTCE selectively exerts potent anti-tumor activity against a relevant subset of TCLs. These findings support the development of a precision immunotherapy approach for patients with UMG1-expressing aggressive hematologic malignancies. - Source: PubMed
Caracciolo DanieleGentile CarloSquillacioti SaraSignorelli StefaniaRiillo CaterinaFaviana PinucciaConforti FrancescoDe Ieso KatiaProcopio ElisabettaAltomare EmanuelaPolerà NicolettaGaetano MariaBalducci EstelleBeganovic OmerTuccillo Franca MariaBonelli PatriziaGrillone KatiaLhermitte LudovicTagliaferri PierosandroTassone Pierfrancesco - Histopathological analysis is a cornerstone of cancer diagnosis, with Hematoxylin and Eosin (H&E) staining routinely acquired for every patient to visualize cell morphology and tissue architecture. On the other hand, multiplex immunofluorescence (mIF) enables more precise cell type identification via proteomic markers, but has yet to achieve widespread clinical adoption due to cost and logistical constraints. To bridge this gap, we introduce MIPHEI (Multiplex Immunofluorescence Prediction from H&E Images), a U-Net-inspired architecture that leverages a ViT pathology foundation model as an encoder to predict mIF signals from H&E images using rich pretrained representations. MIPHEI targets a comprehensive panel of markers spanning nuclear content, immune lineages (T cells, B cells, myeloid), epithelium, stroma, vasculature, and proliferation. We train our model using the publicly available OrionCRC dataset of restained H&E and mIF images from colorectal cancer tissue, and validate it on five independent datasets: HEMIT, PathoCell, IMMUcan, Lizard and PanNuke. On OrionCRC test set, MIPHEI achieves accurate cell-type classification from H&E alone, with F1 scores of 0.93 for Pan-CK, 0.83 for α-SMA, 0.68 for CD3e, 0.36 for CD20, and 0.28 for CD68, substantially outperforming both a state-of-the-art baseline and a random classifier for most markers. Our results indicate that, for some molecular markers, our model captures the complex relationships between nuclear morphologies in their tissue context, as visible in H&E images and molecular markers defining specific cell types. MIPHEI offers a promising step toward enabling cell-type-aware analysis of large-scale H&E datasets, in view of uncovering relationships between spatial cellular organization and patient outcomes. - Source: PubMed
Publication date: 2026/03/07
Balezo GuillaumeTrullo RogerPla Planas AlbertDecencière EtienneWalter Thomas